Adaptimmune Historical Valuation
| ADAP Stock | USD 0.73 0.05 7.35% |
Some fundamental drivers such as market cap or Adaptimmune Therapeutics enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze Adaptimmune Therapeutics valuation indicators such as Working Capital of 0.0 or Enterprise Value of 38.7 M to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of Adaptimmune Therapeutics's future value.
Adaptimmune |
About Adaptimmune Valuation Data Analysis
Valuation is the financial process of determining what Adaptimmune Therapeutics is worth. Adaptimmune Therapeutics valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. Adaptimmune Therapeutics valuation ratios help investors to determine whether Adaptimmune Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Adaptimmune with respect to the benefits of owning Adaptimmune Therapeutics security.
Adaptimmune Therapeutics Valuation Data Chart
Enterprise Value
Enterprise Value (or EV) is usually referred to as Adaptimmune Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Adaptimmune Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of Adaptimmune Therapeutics value than its market capitalization because it takes into account all of Adaptimmune Therapeutics Plc existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
| 0.89 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.76 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.88 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Adaptimmune Stock
| 0.83 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.73 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.59 | PHVS | Pharvaris BV | PairCorr |
| 0.48 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.46 | PMVP | Pmv Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.